Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: full-pipeline trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: 2 US clinical trials tracked, none currently recruiting.
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Hoffmann-La Roche, running 2 of these trials.
Enrollment posture brief
Registry condition estrogen-receptor-positive-her2-negative-locally-advanced-or-metastatic-breast-c
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Hoffmann-La Roche
NCT04546009
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Hoffmann-La Roche
NCT04576455
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hoffmann-La Roche sponsors the most Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Hoffmann-La Roche's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer condition card totals 2 registered trials; most-linked intervention Giredestrant; top US site state Oregon. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.